PRKCD as a Radioligand Therapy Target
PRKCD, protein kinase C delta, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PRKCD staining is highest in thyroid cancer (100% of samples positive), lymphoma (100% of samples positive) and ovarian cancer (92% of samples positive). Clinical status: Clinical-stage (up to phase 2, any modality).
Is PRKCD a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PRKCD expression in cancer
Protein expression of PRKCD across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 1.00 | High | 100% |
| Lymphoma | 0.97 | High | 100% |
| Ovarian Cancer | 0.83 | High | 92% |
| Breast Cancer | 0.81 | High | 100% |
| Melanoma | 0.78 | High | 100% |
| Neuroendocrine Tumors | 0.75 | High | 100% |
| Endometrial Cancer | 0.75 | High | 100% |
| Colorectal Cancer | 0.73 | High | 100% |
| Bladder Cancer | 0.73 | High | 100% |
| Prostate Cancer | 0.73 | High | 100% |
| Pancreatic Cancer | 0.67 | High | 100% |
| Gastric Cancer | 0.67 | High | 100% |
| Cervical Cancer | 0.64 | High | 100% |
| Skin Cancer | 0.61 | High | 100% |
| Glioma | 0.58 | High | 92% |
| Lung Cancer | 0.58 | High | 91% |
| Head and Neck Cancer | 0.56 | High | 100% |
| Kidney Cancer | 0.53 | High | 83% |
| Liver Cancer | 0.50 | Medium | 83% |
| Testicular Cancer | 0.11 | Low | 25% |
Is PRKCD internalized?
Nuclens has not yet extracted internalization evidence for PRKCD. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
PRKCD clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for PRKCD yet. Search ClinicalTrials.gov for PRKCD trials.
PRKCD normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PRKCD in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PRKCD gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: -0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how PRKCD ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.